FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W978172877> ?p ?o ?g. }

• W978172877 endingPage "1835" @default.
• W978172877 startingPage "1835" @default.
• W978172877 abstract "Abstract Ruxolitinib is the only JAK 1/2 inhibitor approved by the FDA for the treatment of myelofibrosis (MF). It has been established that ruxolitinib helps improve disease-related constitutional symptoms and splenomegaly. However, studies have shown that ruxolitinib affects several cytokines (IL1, IL6, and TNF-α) and other immune processes (dendritic cells function and T-cell response) and has been linked to increased incidence of opportunistic and non-opportunistic infections. Here we report our experience at the Cleveland Clinic. A total of 50 patients (pts) with MF treated with ruxolitinib were included. The median age of the cohort was 68 years (range: 41-89), 28 of them were males and 22 were females. According to the Dynamic International Prognostic Scoring System (DIPSS), 5 pts had high risk, 23 had intermediate-2 risk, 21 had intermediate-1 risk and 1 had low risk disease. Of these pts, 18 developed infections during their treatment course. Of these infections, 12 were CTCAEv4.0 grade 1-2 and 6 were grade 3-4. Median age of the group was 66 years-old ranging between 50 and 83. Males=9 and females =9. The group was risk-stratified with DIPSS into high risk (N=3), intermediate-2 risk (N=7) and intermediate-1 risk (N=8).The infection started several months after initiation of JAK inhibitor treatment ranging between 2 weeks to 22 months (median of 8 months). Of note, 10 pts had episodes of infections prior to starting ruxolitinib (pneumonia N=5, cellulitis N=3, oral herpes N=2, UTI N=2, genital herpes N=1, Clostiridium difficile diarrhea N=1, viral diarrhea N=1, neutropenic fever N=1, spontaneous bacterial peritonitis N=1 and psoas muscle abscess N=1) . None of the patients had an active infection at the time of starting ruxolitinib. The median total dose given to the pts who developed grade1-2 infection was 20 mg daily, and for those who had grade 3-4 infection it was 15 mg daily. A variety of infections have been reported including pneumonia (N=4), cellulitisfolliculitis (N=4), Clostridium Difficile diarrhea (N=2), URI (N=1), neutropenic fever (N=1), MSSA bacteremia (N=1), herpes zoster activation (N=2), spontaneous bacterial peritonitis (N=1), perineal abscess (N=1) and one pt had a gluteal abscess after a bone marrow biopsy. Most of these infections resolved using oral or topical antibiotics (N=12). However, 6 pts required hospital admissions, and 5 of them required intravenous antibiotics. One of them required admission to the intensive care unit and two others required surgical interventions. Duration of treatment ranged between 1 to 8 weeks (median 2 weeks). Ruxolitinib had to be discontinued due to the severity of the infection in 2 pts, while the others either had a dose reduction or no dose alteration. Two pts required prophylactic antibiotics; one had recurrent SBP despite antimicrobial prophylaxis, while another pt required acyclovir prophylaxis while receiving glucocorticoids with ruxolitinib with no reactivation of Zoster infection. Predisposing factors for infections included a procedure (BMBx N=1), the concurrent use of other immunosuppressive drugs (steroids N=3, other agents N=3) and the prior use of systemic antibiotics in the pts who had C Diff infections (N=2). Only 2 pts had subsequent infections, one had oral herpes and the other had candida esophagitis which required hospitalization and treatment with IV antifungal drugs while on high dose steroids (dexamethasone 4 mg PO twice daily) for immune thrombocytopenia at the time of infection. Though 5 pts had already died at the time of the chart review, none of them died of infectious complications. In summary, infections can occur in patients treated with ruxolitinib but are generally mild. Most infections resolve after an adequate course of oral antimicrobial therapy suggesting that prophylactic antimicrobial agents may not be necessary or cost-effective in the vast majority of MF pts treated with ruxolitinib. Disclosures No relevant conflicts of interest to declare." @default.
• W978172877 created "2016-06-24" @default.
• W978172877 creator A5006044740 @default.
• W978172877 creator A5016847107 @default.
• W978172877 creator A5032863911 @default.
• W978172877 creator A5050880000 @default.
• W978172877 creator A5052307588 @default.
• W978172877 creator A5055740968 @default.
• W978172877 creator A5064201015 @default.
• W978172877 creator A5064251341 @default.
• W978172877 creator A5075839840 @default.
• W978172877 creator A5077292257 @default.
• W978172877 creator A5082944296 @default.
• W978172877 creator A5089198288 @default.
• W978172877 date "2014-12-06" @default.
• W978172877 modified "2023-10-05" @default.
• W978172877 title "Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib" @default.
• W978172877 doi "https://doi.org/10.1182/blood.v124.21.1835.1835" @default.
• W978172877 hasPublicationYear "2014" @default.
• W978172877 type Work @default.
• W978172877 sameAs 978172877 @default.
• W978172877 citedByCount "2" @default.
• W978172877 countsByYear W9781728772016 @default.
• W978172877 countsByYear W9781728772019 @default.
• W978172877 crossrefType "journal-article" @default.
• W978172877 hasAuthorship W978172877A5006044740 @default.
• W978172877 hasAuthorship W978172877A5016847107 @default.
• W978172877 hasAuthorship W978172877A5032863911 @default.
• W978172877 hasAuthorship W978172877A5050880000 @default.
• W978172877 hasAuthorship W978172877A5052307588 @default.
• W978172877 hasAuthorship W978172877A5055740968 @default.
• W978172877 hasAuthorship W978172877A5064201015 @default.
• W978172877 hasAuthorship W978172877A5064251341 @default.
• W978172877 hasAuthorship W978172877A5075839840 @default.
• W978172877 hasAuthorship W978172877A5077292257 @default.
• W978172877 hasAuthorship W978172877A5082944296 @default.
• W978172877 hasAuthorship W978172877A5089198288 @default.
• W978172877 hasConcept C120665830 @default.
• W978172877 hasConcept C121332964 @default.
• W978172877 hasConcept C126322002 @default.
• W978172877 hasConcept C141071460 @default.
• W978172877 hasConcept C2776112149 @default.
• W978172877 hasConcept C2777753580 @default.
• W978172877 hasConcept C2779134260 @default.
• W978172877 hasConcept C2780007613 @default.
• W978172877 hasConcept C2780076729 @default.
• W978172877 hasConcept C61511704 @default.
• W978172877 hasConcept C71924100 @default.
• W978172877 hasConcept C72563966 @default.
• W978172877 hasConcept C90924648 @default.
• W978172877 hasConceptScore W978172877C120665830 @default.
• W978172877 hasConceptScore W978172877C121332964 @default.
• W978172877 hasConceptScore W978172877C126322002 @default.
• W978172877 hasConceptScore W978172877C141071460 @default.
• W978172877 hasConceptScore W978172877C2776112149 @default.
• W978172877 hasConceptScore W978172877C2777753580 @default.
• W978172877 hasConceptScore W978172877C2779134260 @default.
• W978172877 hasConceptScore W978172877C2780007613 @default.
• W978172877 hasConceptScore W978172877C2780076729 @default.
• W978172877 hasConceptScore W978172877C61511704 @default.
• W978172877 hasConceptScore W978172877C71924100 @default.
• W978172877 hasConceptScore W978172877C72563966 @default.
• W978172877 hasConceptScore W978172877C90924648 @default.
• W978172877 hasIssue "21" @default.
• W978172877 hasLocation W9781728771 @default.
• W978172877 hasOpenAccess W978172877 @default.
• W978172877 hasPrimaryLocation W9781728771 @default.
• W978172877 hasRelatedWork W1869576177 @default.
• W978172877 hasRelatedWork W1883475886 @default.
• W978172877 hasRelatedWork W1959609799 @default.
• W978172877 hasRelatedWork W2077076503 @default.
• W978172877 hasRelatedWork W2143057570 @default.
• W978172877 hasRelatedWork W2304558087 @default.
• W978172877 hasRelatedWork W2805747764 @default.
• W978172877 hasRelatedWork W2810060832 @default.
• W978172877 hasRelatedWork W2898291225 @default.
• W978172877 hasRelatedWork W3113211021 @default.
• W978172877 hasVolume "124" @default.
• W978172877 isParatext "false" @default.
• W978172877 isRetracted "false" @default.
• W978172877 magId "978172877" @default.
• W978172877 workType "article" @default.